Trials suggest that abatacept may delay rheumatoid arthritis in carefully selected high-risk patients, but permanent prevention remains unproven.

Mood changes, anxiety, and brain fog are more common complaints than itching or wheezing, and experts caution that the survey cannot establish cause and effect.

The association remains significant after accounting for estradiol, progesterone, and vasomotor symptoms, though the findings are not yet clinically applicable.

Many patients never connect diabetes with changes in sexual health, leaving clinicians to recognize concerns that may otherwise go unspoken during routine care.

An international panel calls for managing traumatic brain and spinal cord injuries as lifelong conditions, not one-time events.

Patients with head and neck cancer who attended a survivorship clinic before completing RT were more likely to complete treatment on schedule and had better 3-year DFS than those who did not attend.

This digest highlights FDA actions in October related to therapeutics and devices for neurologic illness. For information on approvals in other specialties during 2026, see our FDA Drug Approvals page ...